* Mylan and Biocon to present phase 3 trastuzumab biosimilar
data at the American Society Of Clinical Oncology (ASCO) annual
meeting
The post BRIEF-Mylan and Biocon to present phase 3 trastuzumab biosimilar data at ASCO annual meeting appeared first on NASDAQ.